Stevanato Group S.p.A.

Equities

STVN

IT0005452658

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
27.54 ^USD	+0.07%		+3.03%	+0.92%

Apr. 22	BNP Paribas Exane Initiates Stevanato Group With Outperform Rating	MT
Apr. 04	Stevanato Group Names Ugo Gay as Chief Operations Officer	MT

Stevanato S p A : Group Announces Second Quarter 2021 Financial Results- Establishes Full Year 2021 Guidance -

August 19, 2021 at 08:34 am EDT

Revenue grew 26% to €204.0 million EBITDA increased 52% to €61.0 million; adjusted EBITDA grew 30% to €52.4 million Backlog totaled €738.9 million

Attachments

Original document
Permalink

Disclaimer

Stevanato Group S.p.A. published this content on 19 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2021 12:33:15 UTC.

Latest news about Stevanato Group S.p.A.

BNP Paribas Exane Initiates Stevanato Group With Outperform Rating	Apr. 22	MT
Stevanato Group Names Ugo Gay as Chief Operations Officer	Apr. 04	MT
Stevanato Group S.p.A. Announces the Appointment of Ugo Gay as Chief Operations Officer	Apr. 04	CI
Stevanato Group Closes $379.7 Million Public Share Offering	Mar. 27	MT
Stevanato Group Prices Upsized $330 Million Public Share Offering; Shares Rise	Mar. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Stevanato Group Prices Upsized $330 Million Public Share Offering	Mar. 22	MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	Mar. 21	MT
Stevanato Group Launches Primary, Secondary Offerings; Shares Drop After Hours	Mar. 20	MT
UBS Raises Stevanato Price Target to $34 From $31, Maintains Neutral Rating	Mar. 08	MT
Stevanato Group Q4 Adjusted Earnings Declines, Revenue Rises; Shares Fall	Mar. 07	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 07	MT
Sector Update: Health Care	Mar. 07	MT
Transcript : Stevanato Group S.p.A., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Stevanato Group Q4 Adjusted Earnings Declines, Revenue Rises	Mar. 07	MT
Stevanato Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Stevanato Group S.p.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024	Mar. 07	CI
Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization	Jan. 24	CI
Transcript : Stevanato Group S.p.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM	Jan. 10
Stevanato Group Slips Amid Jefferies' Downgrade to Hold	Nov. 01	MT
Morgan Stanley Adjusts Price Target on Stevanato to $30 From $34, Keeps Equalweight Rating	Nov. 01	MT
Jefferies Downgrades Stevanato to Hold From Buy, Adjusts Price Target to $29 From $39	Nov. 01	MT
How Novo Nordisk makes its weight-loss drug Wegovy	Nov. 01	RE
Transcript : Stevanato Group S.p.A., Q3 2023 Earnings Call, Oct 31, 2023	23-10-31

Chart Stevanato Group S.p.A.

Duration

Period

More charts

Company Profile

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Stevanato Group S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.52 USD

Average target price

35 USD

Spread / Average Target

+27.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STEVANATO GROUP S.P.A.	+0.92%	7.53B
ABBOTT LABORATORIES	-2.31%	185B
MEDTRONIC PLC	-3.20%	105B
BECTON, DICKINSON AND COMPANY	-5.04%	66.59B
DEXCOM, INC.	+0.20%	54.66B
CENCORA, INC.	+17.29%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution